Abstract 1957: Novel substrates for NanoLuc luciferase with improved brightness and signal duration for bioluminescence imagingin vivo
L. Encell,Michael Z. Lin,M. Hall,Thomas A. Kirkland,Yunhee Park,Younghee Oh,L. Liu,Joel R Walker
DOI: https://doi.org/10.1158/1538-7445.SABCS18-1957
2019-07-01
Tumor Biology
Abstract:NanoLuc® luciferase, and its substrate furimazine, are becoming a preferred bioluminescent system in cellular and biochemical assays due to its brightness and glow-type kinetics. The construct Antares, made by fusing NanoLuc to the cyan-excitable orange-red fluorescent protein CyOFP, combines the high catalytic rate of NanoLuc with the high quantum yield and red-shifted emission of CyOFP (584 nm), which is well suited for in vivo imaging. Transgenic mice were created to constituently express Antares and these mice were used to screen coelenterazine analogues for a substrate that showed appropriate distribution and brightness in vivo . Our new Antares (NanoLuc) substrates are administered i.p. , have improved solubility over furimazine, exhibit long (>30 min) signal kinetics, and are brighter than D-luciferin/Luc2 expressed on the same promoters. Citation Format: Joel R. Walker, Yunhee Park, Michael Lin, Thomas A. Kirkland, Mary P. Hall, Lance P. Encell, Younghee Oh, Lan Liu. Novel substrates for NanoLuc luciferase with improved brightness and signal duration for bioluminescence imaging in vivo [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 1957.
Chemistry,Medicine,Biology